Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

AVF-104 takes the form of a glycan-coated nanoparticle designed to ... and is directly comparing the drug – given as either a monthly or bimonthly injection into the eye – with monthly Izervay ...

Advanced mass spectrometry techniques are now enabling more precise glycan analysis, improving therapeutic development and manufacturing processes. This webinar highlights an electron-activated ...

Scientists have found a way to create artificial sugars that could lead to better ways to diagnose and treat diseases more accurately than ever before. Sugars play a crucial role in human health ...

likely contribute to drug-induced neural plasticity in these brain regions. "Notably, altering the levels of these sulfated ...

EO-1022 uses Synaffix’s glycan site-specific conjugation and linker ... However, the body blow of dropping the company’s sole clinical-stage drug means Elevation is now forced to “evaluate ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.

which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND ...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...